ÂÜÀòÂÒÂ×

Andreas Laustsen-Kiel has been working in the field of biotechnology since 2012. Andreas began their career as a Co-Founder of Biosyntia, where they were responsible for business planning in relation to commercialization of novel discovery technology for biocatalysts. Andreas then served as Co-Founder of VenomAb IVS in 2013, and Co-Founder & CTO of Bactolife in 2017. In the same year, they also became Co-founder of Antag Therapeutics. In 2018, they Co-Founded VenomAid Diagnostics, a company specializing in snake venom diagnostics for stratification of snakebite envenomings.

In 2016, Andreas Laustsen-Kiel began working at the Technical University of Denmark as a Professor, Associate Professor, and Postdoctoral Fellow. In 2017, they also became an Advisor in the WHO Working Group on Snakebite Envenoming, and in 2019 they were appointed as a Fellow of Det Unge Akademi. In 2020, they became a Fellow of the Young Academy of Europe.

Andreas Laustsen-Kiel obtained a Certificate of Proficiency in English from the University of Cambridge in December 2007. From 2007 to 2010, they attended the DTU - Technical University of Denmark and earned a B.Sc. Eng. in Human Life Science Engineering. In 2010 and 2011, they attended the Copenhagen Business School for the BioBusiness & Innovation Programme. In 2011 and 2012, they attended Pierre and Marie Curie University and earned an MSc in Chimie Moléculaire. In 2012, they attended the University of California, Davis for Entrepreneurship in the food and healthcare industry. From 2014 to 2016, they attended Københavns Universitet - University of Copenhagen and earned a Doctor of Philosophy (PhD) in Molecular and Cellular Pharmacology.